Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Convergence is going virtual. Join the brightest minds in regulatory online to gain the latest knowledge in the field in an all-virtual experience with workshops, one-on-one expert sessions, and networking communities.
Euro Convergence 2020 is moving towards a rewarding week. We are now offering an enhanced hybrid format with both in-person and online sessions from Monday 26 to Friday 30 October 2020.
Learn how recent changes to the regulation of healthcare products in the EU will impact you as a regulatory professional.
In light of the COVID-19 pandemic, the RAC Board has elected to offer online testing with live online proctoring this summer.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
The Learning Portal will be under maintenance Saturday, 8 August between 6 AM and 6 PM EST. Portal functionality will be unavailable during this window. We apologize for any inconvenience caused during this time.
Posted 01 June 2012 | By Louise Zornoza,
China's State Food and Drug Administration (SFDA) has released a report detailing the adverse event reports it received during 2011. The report notes events involving anti-infective medicines accounted for the higher number of reports, including cephalosporins (34.8%), penicillin (14%) and quinolones (12.2%).
New and serious adverse drug reactions accounted for 17.1% of the total number of reports. Medical institutions were the primary source for such reports, accounting for about 83% of all reported events.
Read more:
2011 adverse reactions report
More Breaking News from RegLink
Tags: Anti-Infectives, Adverse Events, Report, Reporting, 2011
Regulatory Focus newsletters
All the biggest regulatory news and happenings.